{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T21:12:06Z","timestamp":1716325926736},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00059-017-4613-y","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T12:10:43Z","timestamp":1504527043000},"page":"699-712","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Akute und chronische Herzinsuffizienz"],"prefix":"10.1007","volume":"42","author":[{"given":"K.-P.","family":"Kresoja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Kherad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Krackhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Spillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,4]]},"reference":[{"issue":"27","key":"4613_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 37(27):2129\u20132200. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"issue":"8","key":"4613_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00059-016-4496-3","volume":"41","author":"CU Oeing","year":"2016","unstructured":"Oeing CU, Tschope C, Pieske B (2016) Neuerungen der ESC-Leitlinien zur akuten und chronischen Herzinsuffizienz 2016 (The new ESC Guidelines for acute and chronic heart failure 2016). Herz 41(8):655\u2013663. \n                    https:\/\/doi.org\/10.1007\/s00059-016-4496-3","journal-title":"Herz"},{"issue":"14","key":"4613_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJV McMurray","year":"2012","unstructured":"McMurray JJV, Adamopoulos S, Anker SD et\u00a0al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 33(14):1787\u20131847. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehs104","journal-title":"Eur Heart J"},{"issue":"6","key":"4613_CR4","doi-asserted-by":"publisher","first-page":"e003875","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","volume":"10","author":"O Vedin","year":"2017","unstructured":"Vedin O, Lam CSP, Koh AS et\u00a0al (2017) Significance of Ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail 10(6):e3875. \n                    https:\/\/doi.org\/10.1161\/circheartfailure.117.003875","journal-title":"Circ Heart Fail"},{"issue":"9","key":"4613_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","volume":"135","author":"M Obokata","year":"2017","unstructured":"Obokata M, Kane GC, Reddy YNV et al (2017) Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation 135(9):825\u2013838. \n                    https:\/\/doi.org\/10.1161\/circulationaha.116.024822","journal-title":"Circulation"},{"issue":"8","key":"4613_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11886-017-0874-6","volume":"19","author":"C Tsch\u00f6pe","year":"2017","unstructured":"Tsch\u00f6pe C, van Linthout S, Kherad B (2017) Heart failure with preserved ejection fraction and future pharmacological strategies: a glance in the crystal ball. Curr Cardiol Rep 19(8):70. \n                    https:\/\/doi.org\/10.1007\/s11886-017-0874-6","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"4613_CR7","first-page":"34","volume":"21","author":"K-P Kresoja","year":"2016","unstructured":"Kresoja K\u2011P, Tsch\u00f6pe C (2016) Die systolische Herzinsuffizienz \u2013 was gibt es Neues? Jatros Kardiol Gef\u00e4\u00dfmed 21(4):34\u201337","journal-title":"Jatros Kardiol Gef\u00e4\u00dfmed"},{"issue":"16","key":"4613_CR8","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B et\u00a0al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a\u00a0report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation 128(16):e240\u2013e327. \n                    https:\/\/doi.org\/10.1161\/cir.0b013e31829e8776","journal-title":"Circulation"},{"key":"4613_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000509","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B et\u00a0al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. \n                    https:\/\/doi.org\/10.1161\/cir.0000000000000509","journal-title":"Circulation"},{"issue":"11","key":"4613_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371(11):993\u20131004. \n                    https:\/\/doi.org\/10.1056\/nejmoa1409077","journal-title":"N Engl J Med"},{"issue":"10","key":"4613_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M et al (2016) Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 18(10):1228\u20131234. \n                    https:\/\/doi.org\/10.1002\/ejhf.580","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"4613_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","volume":"38","author":"M Bohm","year":"2017","unstructured":"Bohm M, Young R, Jhund PS et al (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart\u00a0J 38(15):1132\u20131143. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw570","journal-title":"Eur Heart J"},{"issue":"38","key":"4613_CR13","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E et al (2015) Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart\u00a0J 36(38):2576\u20132584. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv330","journal-title":"Eur Heart J"},{"issue":"3","key":"4613_CR14","doi-asserted-by":"publisher","first-page":"e002744","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Desai AS et\u00a0al (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (LCZ696) in heart failure with reduced ejection fraction. Clinical Perspective. Circ Heart Fail 9(3):e2744. \n                    https:\/\/doi.org\/10.1161\/circheartfailure.115.002744","journal-title":"Circ Heart Fail"},{"issue":"19","key":"4613_CR15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","volume":"66","author":"J Simpson","year":"2015","unstructured":"Simpson J, Jhund PS, Silva Cardoso J et al (2015) Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J\u00a0Am Coll Cardiol 66(19):2059\u20132071. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2015.08.878","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4613_CR16","doi-asserted-by":"publisher","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","volume":"9","author":"SL Kristensen","year":"2016","unstructured":"Kristensen SL, Preiss D, Jhund PS et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9(1):e2560. \n                    https:\/\/doi.org\/10.1161\/circheartfailure.115.002560","journal-title":"Circ Heart Fail"},{"issue":"5","key":"4613_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB et al (2017) Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a\u00a0post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5):333\u2013340. \n                    https:\/\/doi.org\/10.1016\/s2213-8587(17)30087-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4613_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJV, Desai AS et\u00a0al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54\u201361. \n                    https:\/\/doi.org\/10.1161\/circulationaha.114.013748","journal-title":"Circulation"},{"issue":"1","key":"4613_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B et al (2017) Reduced risk of Hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2(1):79\u201385. \n                    https:\/\/doi.org\/10.1001\/jamacardio.2016.4733","journal-title":"JAMA Cardiol"},{"issue":"36","key":"4613_CR20","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","volume":"35","author":"EA Jankowska","year":"2014","unstructured":"Jankowska EA, Kasztura M, Sokolski M et\u00a0al (2014) Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart\u00a0J 35(36):2468\u20132476. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu235","journal-title":"Eur Heart J"},{"issue":"4","key":"4613_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","volume":"117","author":"JK Ghali","year":"2008","unstructured":"Ghali JK, Anand IS, Abraham WT et al (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117(4):526\u2013535. \n                    https:\/\/doi.org\/10.1161\/circulationaha.107.698514","journal-title":"Circulation"},{"key":"4613_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.115.000345","author":"GD Lewis","year":"2016","unstructured":"Lewis GD, Semigran MJ, Givertz MM et\u00a0al (2016) Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail 9(5). \n                    https:\/\/doi.org\/10.1161\/circheartfailure.115.000345","journal-title":"Circ Heart Fail"},{"issue":"25","key":"4613_CR23","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361(25):2436\u20132448. \n                    https:\/\/doi.org\/10.1056\/nejmoa0908355","journal-title":"N Engl J Med"},{"issue":"11","key":"4613_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart\u00a0J 36(11):657\u2013668. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"issue":"13","key":"4613_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L K\u00f8ber","year":"2016","unstructured":"K\u00f8ber L, Thune JJ, Nielsen JC et\u00a0al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N\u00a0Engl J Med 375(13):1221\u20131230. \n                    https:\/\/doi.org\/10.1056\/nejmoa1608029","journal-title":"N Engl J Med"},{"issue":"18","key":"4613_CR26","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jacc.2008.01.036","volume":"51","author":"C Butter","year":"2008","unstructured":"Butter C, Rastogi S, Minden H\u2011H et al (2008) Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J\u00a0Am Coll Cardiol 51(18):1784\u20131789. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2008.01.036","journal-title":"J Am Coll Cardiol"},{"key":"4613_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijcard.2015.10.208","volume":"203","author":"C Tsch\u00f6pe","year":"2016","unstructured":"Tsch\u00f6pe C, van Linthout S, Spillmann F et\u00a0al (2016) Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. Int J Cardiol 203:1061\u20131066. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2015.10.208","journal-title":"Int J Cardiol"},{"issue":"8","key":"4613_CR28","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/eurheartj\/ehn020","volume":"29","author":"MM Borggrefe","year":"2008","unstructured":"Borggrefe MM, Lawo T, Butter C et al (2008) Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart\u00a0J 29(8):1019\u20131028. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehn020","journal-title":"Eur Heart J"},{"key":"4613_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2016.01.071","volume":"206","author":"M Liu","year":"2016","unstructured":"Liu M, Fang F, Luo XX et al (2016) Improvement of long-term survival by cardiac contractility modulation in heart failure patients: a case-control study. Int J Cardiol 206:122\u2013126. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2016.01.071","journal-title":"Int J Cardiol"},{"issue":"6","key":"4613_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10741-016-9571-6","volume":"21","author":"F Abi-Samra","year":"2016","unstructured":"Abi-Samra F, Gutterman D (2016) Cardiac contractility modulation: a\u00a0novel approach for the treatment of heart failure. Heart Fail Rev 21(6):645\u2013660. \n                    https:\/\/doi.org\/10.1007\/s10741-016-9571-6","journal-title":"Heart Fail Rev"},{"issue":"12","key":"4613_CR31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/europace\/eun257","volume":"10","author":"H N\u00e4gele","year":"2008","unstructured":"N\u00e4gele H, Behrens S, Eisermann C (2008) Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace 10(12):1375\u20131380. \n                    https:\/\/doi.org\/10.1093\/europace\/eun257","journal-title":"Europace"},{"issue":"8","key":"4613_CR32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/europace\/euu050","volume":"16","author":"S R\u00f6ger","year":"2014","unstructured":"R\u00f6ger S, Schneider R, Rudic B et\u00a0al (2014) Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation. Europace 16(8):1205\u20131209. \n                    https:\/\/doi.org\/10.1093\/europace\/euu050","journal-title":"Europace"},{"issue":"4","key":"4613_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","volume":"14","author":"S Linthout van","year":"2017","unstructured":"van Linthout S, Tsch\u00f6pe C (2017) Inflammation \u2013 cause or consequence of heart failure or both? Curr Heart Fail Rep 14(4):251\u2013265. \n                    https:\/\/doi.org\/10.1007\/s11897-017-0337-9","journal-title":"Curr Heart Fail Rep"},{"issue":"4","key":"4613_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11897-009-0039-z","volume":"6","author":"PB Adamson","year":"2009","unstructured":"Adamson PB (2009) Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep 6(4):287\u2013292. \n                    https:\/\/doi.org\/10.1007\/s11897-009-0039-z","journal-title":"Curr Heart Fail Rep"},{"issue":"16","key":"4613_CR35","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCULATIONAHA.116.026184","volume":"135","author":"JT Heywood","year":"2017","unstructured":"Heywood JT, Jermyn R, Shavelle D et al (2017) Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation 135(16):1509\u20131517. \n                    https:\/\/doi.org\/10.1161\/circulationaha.116.026184","journal-title":"Circulation"},{"issue":"5","key":"4613_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/17512433.2017.1299574","volume":"10","author":"J Krzysztofik","year":"2017","unstructured":"Krzysztofik J, Ponikowski P (2017) Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. Expert Rev Clin Pharmacol 10(5):517\u2013534. \n                    https:\/\/doi.org\/10.1080\/17512433.2017.1299574","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"4613_CR37","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","volume":"41","author":"A Nohria","year":"2003","unstructured":"Nohria A, Tsang SW, Fang JC et\u00a0al (2003) Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J\u00a0Am Coll Cardiol 41(10):1797\u20131804","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"4613_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA et\u00a0al (2011) Diuretic strategies in patients with acute decompensated heart failure. N\u00a0Engl J Med 364(9):797\u2013805. \n                    https:\/\/doi.org\/10.1056\/nejmoa1005419","journal-title":"N Engl J Med"},{"issue":"19","key":"4613_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","volume":"56","author":"JC Jentzer","year":"2010","unstructured":"Jentzer JC, DeWald TA, Hernandez AF (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J\u00a0Am Coll Cardiol 56(19):1527\u20131534. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2010.06.034","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"4613_CR40","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"Packer M, O\u2019Connor C, McMurray JJV et\u00a0al (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. N\u00a0Engl J Med 376(20):1956\u20131964. \n                    https:\/\/doi.org\/10.1056\/nejmoa1601895","journal-title":"N Engl J Med"},{"issue":"5","key":"4613_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/eurheartj\/ehv755","volume":"38","author":"A Singh","year":"2017","unstructured":"Singh A, Laribi S, Teerlink JR et\u00a0al (2017) Agents with vasodilator properties in acute heart failure. Eur Heart\u00a0J 38(5):317\u2013325. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv755","journal-title":"Eur Heart J"},{"issue":"3","key":"4613_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1074248414559838","volume":"20","author":"JC Jentzer","year":"2015","unstructured":"Jentzer JC, Coons JC, Link CB et\u00a0al (2015) Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J\u00a0Cardiovasc Pharmacol Ther 20(3):249\u2013260. \n                    https:\/\/doi.org\/10.1177\/1074248414559838","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"9","key":"4613_CR43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D Backer de","year":"2010","unstructured":"de Backer D, Biston P, Devriendt J et\u00a0al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N\u00a0Engl J Med 362(9):779\u2013789. \n                    https:\/\/doi.org\/10.1056\/nejmoa0907118","journal-title":"N Engl J Med"},{"issue":"15","key":"4613_CR44","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1517\/14656566.6.15.2741","volume":"6","author":"JT Parissis","year":"2005","unstructured":"Parissis JT, Filippatos G, Farmakis D et\u00a0al (2005) Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 6(15):2741\u20132751. \n                    https:\/\/doi.org\/10.1517\/14656566.6.15.2741","journal-title":"Expert Opin Pharmacother"},{"key":"4613_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lfs.2017.07.001","volume":"184","author":"J Qiu","year":"2017","unstructured":"Qiu J, Jia L, Hao Y et al (2017) Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci 184:30\u201336. \n                    https:\/\/doi.org\/10.1016\/j.lfs.2017.07.001","journal-title":"Life Sci"},{"issue":"6","key":"4613_CR46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.5603\/CJ.a2016.0100","volume":"23","author":"M Yaman","year":"2016","unstructured":"Yaman M, Arslan U, Kaya A et\u00a0al (2016) Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy. Cardiol\u00a0J 23(6):610\u2013615. \n                    https:\/\/doi.org\/10.5603\/cj.a2016.0100","journal-title":"Cardiol J"},{"issue":"5","key":"4613_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/1053-0770(92)90095-O","volume":"6","author":"JF Butterworth","year":"1992","unstructured":"Butterworth JF, Prielipp RC, Royster RL et\u00a0al (1992) Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J\u00a0Cardiothorac Vasc Anesth 6(5):535\u2013541","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"14","key":"4613_CR48","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann F\u2011J et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N\u00a0Engl J Med 367(14):1287\u20131296. \n                    https:\/\/doi.org\/10.1056\/nejmoa1208410","journal-title":"N Engl J Med"},{"issue":"17","key":"4613_CR49","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/eurheartj\/ehp292","volume":"30","author":"JM Cheng","year":"2009","unstructured":"Cheng JM, den Uil CA, Hoeks SE et al (2009) Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart\u00a0J 30(17):2102\u20132108. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehp292","journal-title":"Eur Heart J"},{"issue":"37","key":"4613_CR50","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F et al (2014) 2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European association for Cardio-thoracic surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart\u00a0J 35(37):2541\u20132619. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu278","journal-title":"Eur Heart J"},{"issue":"3","key":"4613_CR51","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ejhf.668","volume":"19","author":"F Pappalardo","year":"2017","unstructured":"Pappalardo F, Schulte C, Pieri M et al (2017) Concomitant implantation of Impella(\u00ae) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 19(3):404\u2013412. \n                    https:\/\/doi.org\/10.1002\/ejhf.668","journal-title":"Eur J Heart Fail"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4613-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:58:25Z","timestamp":1536699505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,4]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4613"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4613-y","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,4]]}}}